Catalent Biologics Content
-
Catalent Capacity Update April 2025: Fill/Finish
4/25/2025
In this presentation, we will highlight how our proven expertise and simplified execution with development, filling, and analytical under one roof ensure safe, efficacious products reach patients in need.
-
Catalent Capacity Update April 2025: Large Molecule Development
4/22/2025
By leveraging our proprietary non-viral gene insertion technology, GPEx® Lightning ensures rapid development timelines and high-yield production, making it an ideal solution for complex biologics.
-
Mastering QbD For Successful Process Validation Campaigns And Commercial Manufacturing Of Biologics
2/18/2025
In this presentation, industry-leading bioprocess experts explore the challenges and opportunities that arise when implementing Quality by Design (QbD) in biologics development and manufacturing.
-
Formulation Through Manufacturing Under One Roof
2/18/2025
Partner with a CDMO that understands the unique challenges of emerging biopharma, providing expert guidance in formulation development, manufacturing, and regulatory navigation.
-
Catalent Capacity Update October 2024: ADC
10/21/2024
Advance ADC development with the SMARTag® Platform, combining precision bioconjugation and a linker-payload library to enhance the therapeutic index and accelerate timelines.
-
Biologics Analytical Services
5/14/2024
With extensive experience and capabilities, we foster a collaborative environment, developing and implementing innovative analytical methods to efficiently address the testing needs of our partners.
-
High-Throughput Preformulation Development Platform For Biologics
11/21/2019
A high-throughput formulation development for sample preparation and sample analysis enabled a simple and less labor-intensive screening of a broad range of conditions in considerably less time.
-
Strategies To Achieve Successful Approval And Launch
11/18/2019
Four experts share how scale-up, regulatory expectations, demand forecasting, and process validation all play a role in the success of a biologic when embarking upon the commercial manufacturing journey.
-
Ensuring Success In Early Biopharmaceutical Formulation Development
6/10/2019
Biopharmaceuticals tend to be highly unstable. A pilot formulation study at the early drug substance development stage can make things considerably easier at the manufacturing stage.
-
High-Throughput Formulation Development For High-Concentration mAbs
6/10/2019
How a high-throughput, microwell plate platform can be used to economically screen a model IgG1 mAb at 120 mg/ml in 96 formulations while minimizing protein consumed and generating large amount of data.